Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0IIZZN
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
H04L02-Dxd
|
|||||
| Synonyms |
H04L02-Dxd
Click to Show/Hide
|
|||||
| Organization |
Daiichi Sankyo Company, Limited (JP)
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
7.6
|
|||||
| Structure |
|
|||||
| Antibody Name |
H04L02
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
DX-8951 derivative (DXd)
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mc-Gly-Gly-Phe-Gly
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through nucleophilic lysines
|
|||||
| Combination Type |
Deruxtecan
|
|||||